We Offer Worldwide Shipping
Login Wishlist

Morusinol

$1,120

  • Brand : BIOFRON

  • Catalogue Number : BD-P0156

  • Specification : 99.0%(HPLC)

  • CAS number : 62949-93-3

  • Formula : C25H26O7

  • Molecular Weight : 438.5

  • PUBCHEM ID : 5481968

  • Volume : 25mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0156

Analysis Method

HPLC,NMR,MS

Specification

99.0%(HPLC)

Storage

2-8°C

Molecular Weight

438.5

Appearance

Yellow powder

Botanical Source

Structure Type

Flavonoids

Category

SMILES

CC1(C=CC2=C3C(=C(C=C2O1)O)C(=O)C(=C(O3)C4=C(C=C(C=C4)O)O)CCC(C)(C)O)C

Synonyms

2-(2,4-dihydroxyphenyl)-5-hydroxy-3-(3-hydroxy-3-methylbutyl)-8,8-dimethylpyrano[2,3-h]chromen-4-one

IUPAC Name

2-(2,4-dihydroxyphenyl)-5-hydroxy-3-(3-hydroxy-3-methylbutyl)-8,8-dimethylpyrano[2,3-h]chromen-4-one

Applications

Morusinol extracted from Morus alba inhibits arterial thrombosis and modulates platelet activation for the treatment of cardiovascular disease. PUMID/DOI:DOI: 10.5551/jat.10058 J Atheroscler Thromb. 2012;19(6):516-22. Morus alba (white mulberry) has been used in traditional Chinese medicine as an anti-headache, diuretic, expectorant, and anti-diabetic agent. In previous studies, extracts of Morus alba demonstrated favorable biological properties, such as antioxidant activity, suppression of lipoxygenase (LOX)-1, cytotoxicity against cancer cells, and inhibition of the invasion and migration of cancer cells.AIM:This study further evaluated the effects of morusinol, a flavonoid derived from Morus alba root bark, on platelet aggregation and thromboxane B(2) (TXB(2) formation in vitro and thrombus formation in vivo.METHODS:The antiplatelet potential of morusinol was measured using in vitro rabbit platelet aggregation and TXB(2) formation assays. Arterial thrombus formation was investigated using an in vivo ferric chloride (FeCl(3)-induced thrombosis model.RESULTS:Morusinol significantly inhibited collagen- and arachidonic acid-induced platelet aggregation and TXB(2) formation in cultured platelets in a concentration-dependent manner. Thrombus formation was reduced by 32.1, 42.0, and 99.0% for collagen-induced TXB(2) formation, and 8.0, 24.1, and 29.2% for arachadonic acid-induced TXB(2) formation, with 5, 10, and 30 ?g/mL morusinol, respectively. Moreover, oral morusinol (20 mg/kg) or aspirin (20 mg/kg) for three days significantly increased the time to occlusion in vivo by 20.3±5.0 or 6.8±2.9 min, respectively, compared with the control (1% CMC, carboxymethyl cellulose).CONCLUSION:Taken together, these results indicate that morusinol may significantly inhibit arterial thrombosis in vivo due to antiplatelet activity. Thus, morusinol may exert beneficial effects on transient ischemic attacks or stroke via the modulation of platelet activation. Evaluation of anti-inflammatory activity of prenylated substances isolated from Morus alba and Morus nigra. PUMID/DOI:DOI: 10.1021/np401025f J Nat Prod. 2014 Jun 27;77(6):1297-303. Chromatographic separation of root extracts of Morus alba and M. nigra led to the identification of the 2-arylbenzofurans moracin C (1), mulberrofuran Y (2), and mulberrofuran H (3), and the prenylated flavonoids kuwanon E (4), kuwanon C (5), sanggenon H (6), cudraflavone B (7), and morusinol (8), and the Diels-Alder adducts soroceal (9), and sanggenon E (10). The cytotoxicity and their antiphlogistic activity, determined as the attenuation of the secretion of TNF-α and IL-1β and the inhibition of NF-κB nuclear translocation in LPS-stimulated macrophages, were evaluated for compounds 1-10.

Density

1.3±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

240.9±25.0 °C

Boiling Point

699.6±55.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C25H26O7/c1-24(2,30)9-7-16-21(29)20-18(28)12-19-15(8-10-25(3,4)32-19)23(20)31-22(16)14-6-5-13(26)11-17(14)27/h5-6,8,10-12,26-28,30H,7,9H2,1-4H3

InChl Key

AFOKZNPZDXHDHD-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:62949-93-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

28932417

Abstract

In the title compound, [Mn3(C14H12ClN2O)3(CH3O)3O]ClO4·1.1CH2Cl2·0.9C4H10O, the cation consists of a central Mn3O core with μ2-methano­late bridging between adjacent MnIII atoms, thus giving each MnIII atom a mer-O3 coordination environment. Six-coordination for each MnIII atom is provided by the deprotonated Schiff base ligand (E)-4-chloro-2-({[2-(pyridin-2-yl)eth­yl]imino}­meth­yl)phenolate. There are extensive C—H⋯O and C—H⋯Cl inter­actions, which link the cations, anions, and solvent mol­ecules into a three-dimensional array.

KEYWORDS

crystal structure, trinuclear manganese complex, Jahn-Teller distortion, Schiff base complex

Title

Rita Egekenze,a,* Yilma Gultneh,a and Ray J. Butchera

Author

Rita Egekenze,a,* Yilma Gultneh,a and Ray J. Butchera

Publish date

2017 Jul 1;

PMID

21193244

Abstract

One in five older adults in Taiwan have been diagnosed with diabetes. This study drew on disability data for 5,121 nationally representative middle-aged and older adults from the 1996-2003 Survey of Health and Living Status of the Elderly in Taiwan (SHLSET). By employing cohort sequential design and multilevel models, it combined cross-sectional and longitudinal evidence to characterize the age trajectory of physical disability from midlife to older adulthood and to discern the extent to which diabetes contributes to the variation in that trajectory. The main effects of diabetes and diabetes × age interaction in the fully controlled model provide evidence that diabetes independently and consistently changes physical functioning over and above natural aging processes in Taiwanese adults. In addition, while adding diabetes in the age trajectory of physical disability explained 3.2% and 1.6% of the variance in levels of and linear changes in physical disability trajectory, respectively, further adding follow-up status, sociodemographic factors and comorbidities altogether explained 40.5% and 29.1% of the variance in levels of and linear changes in that trajectory. These results imply that preventing the incidence of diabetes-related comorbidities may reduce the deterioration in both levels of and rates of change in physical disability.

KEYWORDS

Cohort-sequential design (accelerated longitudinal design), Multilevel modeling, Taiwan elders, Diabetes

Title

Diabetes-Related Change in Physical Disability from Midlife to Older Adulthood: Evidence from 1996-2003 Survey of Health and Living Status of the Elderly in Taiwan

Author

Ching-Ju Chiu, PhD,1 Linda A. Wray, PhD,1 and Mary Beth Ofstedal, PhD2

Publish date

2012 Mar 1.

PMID

22719288

Abstract

The 1,10-phenanthroline-chelated Zn atom in the polymeric title compound, {[Zn(C7H4O6S)(C12H8N2)(H2O)2]·1.5H2O}n, is connected to the sulfonate O atom of one 4-hy­droxy-3-sulfonato­benzoate dianion and to the carboxyl­ate O atom of another dianion. It is also coordinated by two water mol­ecules in an overall octa­hedral environment. The dianion links adjacent metal atoms into a chain running along [110]. The chains are linked by O—H⋯O hydrogen bonds into a three-dimensional network.

Title

catena-Poly[[[diaqua­(1,10-phenanthroline-κ2 N,N′)zinc]-μ-4-hy­droxy-3-sulfonato­benzoato-κ2 O 3:O 1] sesquihydrate]

Author

Xiang-Qian Fang,a Shan Gao,a and Seik Weng Ngb,c,*

Publish date

2012 Jun 1